Go Pro
→ Should You Convert a Traditional IRA to a Roth After 60? (From SmartAsset) (Ad)tc pixel
OTCMKTS:CYDY

CytoDyn Q4 2025 Earnings Report

CytoDyn logo
$0.23 0.00 (0.00%)
As of 09/25/2026 03:59 PM Eastern
ProfileEarnings History

CytoDyn EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CytoDyn Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CytoDyn Announcement Details

Quarter
Q4 2025
Date
7/25/2025
Time
After Market Closes
Conference Call Date
Friday, July 25, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

CytoDyn's Q1 2027 earnings is estimated for Thursday, October 8, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, October 7, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

CytoDyn's Q4 2025 Annual reportAnnual report
(10-K)

CytoDyn Earnings Headlines

CytoDyn (OTCMKTS:CYDY) Shares Pass Below 50-Day Moving Average - Here's What Happened
September 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31030345
CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th
September 15, 2026  |  financialpost.comF
Should You Convert a Traditional IRA to a Roth After 60?
Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-free qualified withdrawals, and no lifetime required minimum distributions. The catch: converting triggers ordinary income tax in the year you convert, and the decision cannot be reversed. The right move depends on your income, tax bracket, and retirement timeline.tc pixel
 |  SmartAsset (Ad)
CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th
September 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/15/3362079/0/en/cytodyn-inc-to-present-at-the-life-sciences-investor-forum-on-september-17th.html
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354141/19782/en/cytodyn-closes-16-5-million-financing-to-fund-continued-development-of-leronlimab.html
Kessler Topaz Meltzer & Check, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of CytoDyn Inc. common stock
July 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kessler-topaz-meltzer--check-llp-announces-proposed-class-action-settlement-on-behalf-of-purchasers-of-cytodyn-inc-common-stock-302817255.html
See More CytoDyn Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CytoDyn? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CytoDyn and other key companies, straight to your email.

About CytoDyn

CytoDyn (OTCMKTS:CYDY) is a biotechnology company focused on developing leronlimab, an investigational monoclonal antibody designed to target and block CCR5, a receptor involved in immune-cell signaling. The company is headquartered in Vancouver, Washington.

Leronlimab has been studied as a potential treatment for HIV infection and other diseases in which CCR5 may play a role. CytoDyn has also explored the compound in oncology and inflammatory conditions, including certain forms of cancer and other immune-related disorders. The company does not currently market an FDA-approved product, and leronlimab remains an investigational therapy.

CytoDyn acquired rights to leronlimab, formerly known as PRO 140, from Progenics Pharmaceuticals and has conducted clinical development programs involving the drug. Its research activities are primarily focused on advancing leronlimab through regulatory and clinical development for potential use in the United States and other markets.

View CytoDyn Profile
Earnings Tools